Bipartisan congressional lawmakers have filed a bill they say is intended to codify into law an executive order President Donald Trump issued to streamline research and access into psychedelic medicine.
Reps. Morgan Luttrell (R-TX), Lou Correa (D-CA), Jack Bergman (R-MI) and Michael McCaul (R-TX) introduced the Initiating Biomedical Outcomes to Garner Advancements into Innovative Neuroplastogen Efficacy (IBOGAINE) Act on Tuesday.
The legislation would direct the attorney general to “take all necessary steps to determine whether to transfer ibogaine and ibogaine compounds” from schedule I to schedule II of the Controlled Substances Act (CSA) within 60 days. It also says that the attorney general and the health and human services secretary would need to initiate proceedings to reschedule any other Schedule I substances that complete Phase 3 clinical trials.
“Last month, President Trump ushered in a new era of treatment options for our veterans with his executive order accelerating medical treatments for serious mental illness. Now we must codify it into law and ensure this progress is not lost,” Luttrell said in a press release. “Psychedelic therapy has helped me and countless other veterans, improving our lives for the better. As we fight to combat our veteran suicide crisis, this breakthrough
Read full article on Marijuana Moment
